董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gabriele Marco Antonio Cerrone | 男 | Executive Chairman | 47 | 28.46万美元 | 未持股 | 2020-06-17 |
| Willy Simon | 男 | Non-Executive Director | 69 | 4.85万美元 | 未持股 | 2020-06-17 |
| Vaseem A. Palejwala | 男 | Director, Clinical operations | 36 | 未披露 | 未持股 | 2020-06-17 |
| Gregor MacRae | -- | Non-Executive Director | 58 | 未披露 | 未持股 | 2020-06-17 |
| Kunwar Shailubhai | 男 | Chief Executive Officer, Chief Scientific Officer and Executive Director | 63 | 81.00万美元 | 未持股 | 2020-06-17 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Tiziano Lazzaretti | 男 | Chief Financial Officer | 36 | 17.59万美元 | 未持股 | 2020-06-17 |
| Jules S. Jacob | 男 | Senior Director, CMC & Non-Clinical Development | 36 | 未披露 | 未持股 | 2020-06-17 |
| Kunwar Shailubhai | 男 | Chief Executive Officer, Chief Scientific Officer and Executive Director | 63 | 81.00万美元 | 未持股 | 2020-06-17 |
董事简历
中英对照 | 中文 | 英文- Gabriele Marco Antonio Cerrone
-
Gabriele Marco Antonio Cerrone是该公司的创始人，自2014年4月以来一直担任其执行主席。Cerrone先生在肿瘤学、传染病和分子诊断领域创立了九家生物技术公司，并在纳斯达克上市了其中六家，在AIM上市了一家。Cerrone先生联合创立了Trovagene，Inc.，这是一家分子诊断公司，并担任其联合主席。Cerrone先生是Synergy Pharmaceuticals，Inc.和Callisto Pharmaceuticals，Inc.的联合创始人和董事长，并担任SIGATechnologies，Inc.的董事和领导该公司的重组。Cerrone先生共同创立了Fermavir Pharmaceuticals，Inc.，并担任董事长，直到2007年9月该公司与Inhibitex，Inc.合并Cerrone曾担任Inhibitex，Inc.董事，直到2012年该公司以25亿美元出售给百时美施贵宝（Bristol Myer Squibb）。Cerrone先生毕业于纽约大学斯特恩商学院（New York University&8217；s Stern School of Business），获得工商管理硕士学位（MBA）。
Gabriele Marco Antonio Cerrone is the Founder of the company and has been its Executive Chairman since April 2014. Mr. Cerrone has founded nine biotechnology companies in oncology, infectious diseases and molecular diagnostics, and has listed six of these companies on Nasdaq and one on AIM. Mr. Cerrone co-founded Trovagene, Inc. a molecular diagnostic company and served as its co-chairman. Mr. Cerrone was a co-founder and served as chairman of both Synergy Pharmaceuticals, Inc. and Callisto Pharmaceuticals, Inc., and was a director of and led the restructuring of Siga Technologies, Inc.. Mr. Cerrone co-founded FermaVir Pharmaceuticals, Inc. and served as chairman until its merger in September 2007 with Inhibitex, Inc. Mr. Cerrone served as a director of Inhibitex, Inc. until its US$2.5bn sale to Bristol Myer Squibb in 2012. Mr. Cerrone graduated from New York University’s Stern School of Business with a master in business administration MBA). - Gabriele Marco Antonio Cerrone是该公司的创始人，自2014年4月以来一直担任其执行主席。Cerrone先生在肿瘤学、传染病和分子诊断领域创立了九家生物技术公司，并在纳斯达克上市了其中六家，在AIM上市了一家。Cerrone先生联合创立了Trovagene，Inc.，这是一家分子诊断公司，并担任其联合主席。Cerrone先生是Synergy Pharmaceuticals，Inc.和Callisto Pharmaceuticals，Inc.的联合创始人和董事长，并担任SIGATechnologies，Inc.的董事和领导该公司的重组。Cerrone先生共同创立了Fermavir Pharmaceuticals，Inc.，并担任董事长，直到2007年9月该公司与Inhibitex，Inc.合并Cerrone曾担任Inhibitex，Inc.董事，直到2012年该公司以25亿美元出售给百时美施贵宝（Bristol Myer Squibb）。Cerrone先生毕业于纽约大学斯特恩商学院（New York University&8217；s Stern School of Business），获得工商管理硕士学位（MBA）。
- Gabriele Marco Antonio Cerrone is the Founder of the company and has been its Executive Chairman since April 2014. Mr. Cerrone has founded nine biotechnology companies in oncology, infectious diseases and molecular diagnostics, and has listed six of these companies on Nasdaq and one on AIM. Mr. Cerrone co-founded Trovagene, Inc. a molecular diagnostic company and served as its co-chairman. Mr. Cerrone was a co-founder and served as chairman of both Synergy Pharmaceuticals, Inc. and Callisto Pharmaceuticals, Inc., and was a director of and led the restructuring of Siga Technologies, Inc.. Mr. Cerrone co-founded FermaVir Pharmaceuticals, Inc. and served as chairman until its merger in September 2007 with Inhibitex, Inc. Mr. Cerrone served as a director of Inhibitex, Inc. until its US$2.5bn sale to Bristol Myer Squibb in 2012. Mr. Cerrone graduated from New York University’s Stern School of Business with a master in business administration MBA).
- Willy Simon
-
Willy Simon自2015年11月起担任公司非执行董事。Simon先生从2007年8月开始担任Bever Holding B.V.的非执行主席，这是一家专注于房地产开发的荷兰上市上市公司。Simon先生从2000年1月到2002年7月担任Fortis Investment Management的首席执行官。Simon先生从1975年8月到1983年12月在KredietBank N.V.工作，从1984年1月到1996年12月在Citibank London工作，然后从1997年1月到1999年12月担任Generale Bank NL的董事会执行成员。从2004年7月到2012年4月，他曾担任Redi&Partners公司（基金的基金）的非执行董事。Simon从2012年4月到2014年4月担任AIM-Traded Velox3plc（前身为24/7Gaming Group Holdings plc，一家专注于为移动游戏行业发布和开发游戏软件的公司）董事长。Simon从2003年12月到2111年9月担任PlayLogic Entertainment Inc.（一家纳斯达克上市公司，专注于开发、出版和销售交互式软件游戏）董事。Simon从2102年9月到2004年12月担任Bank Oyens&Van Eeghen董事长。Simon先生拥有卢万大学（University of Louvain）的法律学位和斯特拉斯堡高等研究学院（Institut des Hautes Etudes Europe&233；Ennes）的欧洲法律和经济学研究生学位。
Willy Simon,has been a director of Okyo Pharma Limited since November 2015. He is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. He was chairman of AIM-traded Velox3 plc (formerly 24/7 Gaming Group Holdings plc) until 2014 and had been a director of Playlogic Entertainment Inc., a Nasdaq OTC listed company. Willy Simon has been the chairman of Bever Holdings, a company listed in Amsterdam, since 2006 and Chairman of Ducat Maritime since 2015. He is also a non-executive director of Tiziana Life Sciences Limited, AccuStem Sciences Inc and Rasna Therapeutics Inc. - Willy Simon自2015年11月起担任公司非执行董事。Simon先生从2007年8月开始担任Bever Holding B.V.的非执行主席，这是一家专注于房地产开发的荷兰上市上市公司。Simon先生从2000年1月到2002年7月担任Fortis Investment Management的首席执行官。Simon先生从1975年8月到1983年12月在KredietBank N.V.工作，从1984年1月到1996年12月在Citibank London工作，然后从1997年1月到1999年12月担任Generale Bank NL的董事会执行成员。从2004年7月到2012年4月，他曾担任Redi&Partners公司（基金的基金）的非执行董事。Simon从2012年4月到2014年4月担任AIM-Traded Velox3plc（前身为24/7Gaming Group Holdings plc，一家专注于为移动游戏行业发布和开发游戏软件的公司）董事长。Simon从2003年12月到2111年9月担任PlayLogic Entertainment Inc.（一家纳斯达克上市公司，专注于开发、出版和销售交互式软件游戏）董事。Simon从2102年9月到2004年12月担任Bank Oyens&Van Eeghen董事长。Simon先生拥有卢万大学（University of Louvain）的法律学位和斯特拉斯堡高等研究学院（Institut des Hautes Etudes Europe&233；Ennes）的欧洲法律和经济学研究生学位。
- Willy Simon,has been a director of Okyo Pharma Limited since November 2015. He is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. He was chairman of AIM-traded Velox3 plc (formerly 24/7 Gaming Group Holdings plc) until 2014 and had been a director of Playlogic Entertainment Inc., a Nasdaq OTC listed company. Willy Simon has been the chairman of Bever Holdings, a company listed in Amsterdam, since 2006 and Chairman of Ducat Maritime since 2015. He is also a non-executive director of Tiziana Life Sciences Limited, AccuStem Sciences Inc and Rasna Therapeutics Inc.
- Vaseem A. Palejwala
-
VaseemA.Palejwala自2017年1月起担任公司非临床研究总监，在药物发现和开发方面拥有18年的经验。Palejwala博士目前还担任Rasna Therapeutics，Inc.的发现和临床前研究总监。Palejwala博士于2015年1月至2017年1月担任发现和临床前研究总监，并于2012年12月至2014年12月担任发现和临床前研究副总监，在Synergy PharmaceuticalsInc.，他为建立胃肠道相关的临床前动物模型做出了积极贡献，以测试Plecanatide和Dolcanatide的疗效并验证其作用机制。Palejwala博士还积极参与了NDA的Trulance®；的非临床药理学部分的准备工作。从2001年到2012年，他曾担任Sanofi S.A.（跨国制药公司）的发现科学家/经理，在那里他曾推进免疫学、炎症、肿瘤学、CNS和代谢紊乱的小分子和生物程序，也曾为建立和管理高通量基因表达谱平台能力做出贡献。Palejwala博士拥有孟买大学（Bombay University）微生物学和化学学位，以及巴罗达Maharaja Sayajirao大学（the Maharaja Sayajirao University of Baroda）微生物学理学硕士学位和博士学位。
Vaseem A. Palejwala has served as Director, Non-Clinical Studies of the company since January 2017 and has 18 years of experience in drug discovery and development. Dr. Palejwala also currently serves as director of discovery and preclinical research at Rasna Therapeutics, Inc. From January 2015 to January 2017 Dr. Palejwala served as director of discovery and preclinical research, and from December 2012 to December 2014 served as associate director of discovery and preclinical research, at Synergy Pharmaceuticals Inc. where he actively contributed to establishing GI tract-related preclinical animal models for testing the efficacy and validating the mechanism of action for both plecanatide and dolcanatide. Dr. Palejwala also actively participated in preparation of the nonclinical pharmacology section of the NDA for Trulance®. From 2001 to 2012 Dr. Palejwala served as discovery scientist/manager at Sanofi S.A., a multinational pharmaceutical company, where he advanced both small molecule and biologic programs in immunology, inflammation, oncology, CNS and metabolic disorders and also contributed to establishing and managing high-throughput gene expression profiling platform capabilities. Dr. Palejwala holds a degree in microbiology and chemistry from Bombay University, as well as a master of science degree in microbiology and a Ph.D. in microbiology from the Maharaja Sayajirao University of Baroda. - VaseemA.Palejwala自2017年1月起担任公司非临床研究总监，在药物发现和开发方面拥有18年的经验。Palejwala博士目前还担任Rasna Therapeutics，Inc.的发现和临床前研究总监。Palejwala博士于2015年1月至2017年1月担任发现和临床前研究总监，并于2012年12月至2014年12月担任发现和临床前研究副总监，在Synergy PharmaceuticalsInc.，他为建立胃肠道相关的临床前动物模型做出了积极贡献，以测试Plecanatide和Dolcanatide的疗效并验证其作用机制。Palejwala博士还积极参与了NDA的Trulance®；的非临床药理学部分的准备工作。从2001年到2012年，他曾担任Sanofi S.A.（跨国制药公司）的发现科学家/经理，在那里他曾推进免疫学、炎症、肿瘤学、CNS和代谢紊乱的小分子和生物程序，也曾为建立和管理高通量基因表达谱平台能力做出贡献。Palejwala博士拥有孟买大学（Bombay University）微生物学和化学学位，以及巴罗达Maharaja Sayajirao大学（the Maharaja Sayajirao University of Baroda）微生物学理学硕士学位和博士学位。
- Vaseem A. Palejwala has served as Director, Non-Clinical Studies of the company since January 2017 and has 18 years of experience in drug discovery and development. Dr. Palejwala also currently serves as director of discovery and preclinical research at Rasna Therapeutics, Inc. From January 2015 to January 2017 Dr. Palejwala served as director of discovery and preclinical research, and from December 2012 to December 2014 served as associate director of discovery and preclinical research, at Synergy Pharmaceuticals Inc. where he actively contributed to establishing GI tract-related preclinical animal models for testing the efficacy and validating the mechanism of action for both plecanatide and dolcanatide. Dr. Palejwala also actively participated in preparation of the nonclinical pharmacology section of the NDA for Trulance®. From 2001 to 2012 Dr. Palejwala served as discovery scientist/manager at Sanofi S.A., a multinational pharmaceutical company, where he advanced both small molecule and biologic programs in immunology, inflammation, oncology, CNS and metabolic disorders and also contributed to establishing and managing high-throughput gene expression profiling platform capabilities. Dr. Palejwala holds a degree in microbiology and chemistry from Bombay University, as well as a master of science degree in microbiology and a Ph.D. in microbiology from the Maharaja Sayajirao University of Baroda.
- Gregor MacRae
-
Gregor MacRae是一名商业顾问，专门研究税收和跨境解决方案。目前，Gregor是Appledore Wealth Management LLP（一家总部位于伦敦的高净值商业咨询合伙企业）高级合伙人。此前，Gregor曾担任一家国际信托公司董事，包括担任税务和私人客户集团董事总经理。Gregor持有University of Birmingham LLB Hons法律学位，是一名合格特许会计师ICAEW。
Gregor MacRae is a business adviser, who specialises in taxation and cross border solutions. Presently, Gregor is the Senior Partner of Appledore Wealth Management LLP which is a London-based high net worth business advisory partnership. Previously, Gregor has been a director of an international trust company which included holding the position of managing director of the taxation and private client groups. Gregor holds a degree in Law from University of Birmingham LLB Hons and is a qualified Chartered Accountant ICAEW. - Gregor MacRae是一名商业顾问，专门研究税收和跨境解决方案。目前，Gregor是Appledore Wealth Management LLP（一家总部位于伦敦的高净值商业咨询合伙企业）高级合伙人。此前，Gregor曾担任一家国际信托公司董事，包括担任税务和私人客户集团董事总经理。Gregor持有University of Birmingham LLB Hons法律学位，是一名合格特许会计师ICAEW。
- Gregor MacRae is a business adviser, who specialises in taxation and cross border solutions. Presently, Gregor is the Senior Partner of Appledore Wealth Management LLP which is a London-based high net worth business advisory partnership. Previously, Gregor has been a director of an international trust company which included holding the position of managing director of the taxation and private client groups. Gregor holds a degree in Law from University of Birmingham LLB Hons and is a qualified Chartered Accountant ICAEW.
- Kunwar Shailubhai
-
Kunwar Shailubhai，2008年7月起担任公司首席科学官。2004年3月至2008年7月，他担任Synergy DE药物开发部高级副总裁。2003年5月至2004年3月，他担任Synergy DE研发部执行副总裁。2001至2003年4月，他担任Synergy DE药物开发部副总裁，主要负责临床前开发治疗结肠癌和胃肠道炎症药物的GC-C激动剂项目。1993至2000年，他在Monsanto Company担任癌症化学预防组的负责人。他之前在国立卫生研究院（National Institutes of Health）担任高级教员，且在University of Maryland担任助理教授。他1984年获得印度University of Baroda微生物学博士学位，2001年获得圣路易斯University of Missouri的工商管理硕士学位。
Kunwar Shailubhai has served as Chief Executive Officer, Chief Scientific Officer and Executive Director of the company since 2008. Since April, 2017 Dr. Shailubhai has served as Chief Executive Officer of Rasna Therapeutics, Inc. Dr. Shailubhai was a co-founder of Synergy Pharmaceuticals Inc. and served as Chief Scientific Officer from July 2008 to May 2017. From March 2004 until July 2008 Dr. Shailubhai served as Senior Vice President, Drug Discovery of Synergy, which at that time was a subsidiary of Callisto Pharmaceuticals, Inc. “Synergy DE”. From May 2003 until March 2004 Dr. Shailubhai served as executive vice president, R&D of Synergy DE. From 2001 to April 2003 Dr. Shailubhai held the position of Vice President, Drug Discovery at Synergy DE where he was chiefly responsible for the preclinical development of its GC-C agonist program for drugs to treat colon cancer and GI inflammation. Between 1993 and 2000 he was with Monsanto Company, serving as group leader of the cancer chemoprevention group. Dr. Shailubhai previously served as a senior staff fellow at the National Institutes of Health, and as an assistant professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology in 1984 from the University of Baroda, India, and his MBA in 2001 from the University of Missouri, St. Louis. - Kunwar Shailubhai，2008年7月起担任公司首席科学官。2004年3月至2008年7月，他担任Synergy DE药物开发部高级副总裁。2003年5月至2004年3月，他担任Synergy DE研发部执行副总裁。2001至2003年4月，他担任Synergy DE药物开发部副总裁，主要负责临床前开发治疗结肠癌和胃肠道炎症药物的GC-C激动剂项目。1993至2000年，他在Monsanto Company担任癌症化学预防组的负责人。他之前在国立卫生研究院（National Institutes of Health）担任高级教员，且在University of Maryland担任助理教授。他1984年获得印度University of Baroda微生物学博士学位，2001年获得圣路易斯University of Missouri的工商管理硕士学位。
- Kunwar Shailubhai has served as Chief Executive Officer, Chief Scientific Officer and Executive Director of the company since 2008. Since April, 2017 Dr. Shailubhai has served as Chief Executive Officer of Rasna Therapeutics, Inc. Dr. Shailubhai was a co-founder of Synergy Pharmaceuticals Inc. and served as Chief Scientific Officer from July 2008 to May 2017. From March 2004 until July 2008 Dr. Shailubhai served as Senior Vice President, Drug Discovery of Synergy, which at that time was a subsidiary of Callisto Pharmaceuticals, Inc. “Synergy DE”. From May 2003 until March 2004 Dr. Shailubhai served as executive vice president, R&D of Synergy DE. From 2001 to April 2003 Dr. Shailubhai held the position of Vice President, Drug Discovery at Synergy DE where he was chiefly responsible for the preclinical development of its GC-C agonist program for drugs to treat colon cancer and GI inflammation. Between 1993 and 2000 he was with Monsanto Company, serving as group leader of the cancer chemoprevention group. Dr. Shailubhai previously served as a senior staff fellow at the National Institutes of Health, and as an assistant professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology in 1984 from the University of Baroda, India, and his MBA in 2001 from the University of Missouri, St. Louis.
高管简历
中英对照 | 中文 | 英文- Tiziano Lazzaretti
Tiziano Lazzaretti自2016年3月起分别担任公司和Rasna Therapeutics，Inc.的首席财务官。Lazzaretti先生在梦百合和制药行业拥有丰富的经验，并于2011年至2016年从Teva Ratiopharm分拆的Pharmentis SRL加入公司，担任集团财务总监。Lazzaretti先生是Alliance Boots梦百合的执行董事，该公司是一家由国际制药公司领导的健康和美容集团。Lazzaretti先生在Snia SpA、埃森哲（Accenture）和菲亚特集团（Fiat Group）担任高级职位。Lazzaretti先生在意大利都灵大学（University of Turin）获得会计学和金融学理学学士学位，在米兰博科尼大学（Bocconi University）获得工商管理硕士学位，并在伦敦商学院（London Business School）学习企业金融学。
Tiziano Lazzaretti has served as Chief Financial Officer of the company and Rasna Therapeutics, Inc., respectively, since March 2016. Mr. Lazzaretti has extensive experience in the healthcare and pharmaceutical industries and joined the company from Pharmentis Srl, a spin-off from Teva Ratiopharm, where he served as group finance director from 2011 to 2016. Mr. Lazzaretti was executive director at Alliance Boots Healthcare, an international pharmacy-led health and beauty group. Mr. Lazzaretti held senior positions at SNIA Spa, Accenture, and Fiat Group. Mr. Lazzaretti received his bachelor of science BSc Hons in accounting and finance from the University of Turin, Italy, was awarded a master in business administration from Bocconi University, Milan and studied corporate finance at the London Business School.- Tiziano Lazzaretti自2016年3月起分别担任公司和Rasna Therapeutics，Inc.的首席财务官。Lazzaretti先生在梦百合和制药行业拥有丰富的经验，并于2011年至2016年从Teva Ratiopharm分拆的Pharmentis SRL加入公司，担任集团财务总监。Lazzaretti先生是Alliance Boots梦百合的执行董事，该公司是一家由国际制药公司领导的健康和美容集团。Lazzaretti先生在Snia SpA、埃森哲（Accenture）和菲亚特集团（Fiat Group）担任高级职位。Lazzaretti先生在意大利都灵大学（University of Turin）获得会计学和金融学理学学士学位，在米兰博科尼大学（Bocconi University）获得工商管理硕士学位，并在伦敦商学院（London Business School）学习企业金融学。
- Tiziano Lazzaretti has served as Chief Financial Officer of the company and Rasna Therapeutics, Inc., respectively, since March 2016. Mr. Lazzaretti has extensive experience in the healthcare and pharmaceutical industries and joined the company from Pharmentis Srl, a spin-off from Teva Ratiopharm, where he served as group finance director from 2011 to 2016. Mr. Lazzaretti was executive director at Alliance Boots Healthcare, an international pharmacy-led health and beauty group. Mr. Lazzaretti held senior positions at SNIA Spa, Accenture, and Fiat Group. Mr. Lazzaretti received his bachelor of science BSc Hons in accounting and finance from the University of Turin, Italy, was awarded a master in business administration from Bocconi University, Milan and studied corporate finance at the London Business School.
- Jules S. Jacob
JulesS.Jacob自2017年7月起分别担任公司和Rasna Therapeutics，Inc.的CMC和非临床开发高级总监，拥有超过25年的药物开发经验。此前，Jacob先生于2009年3月至2017年7月担任药物输送技术平台公司Aprecia Pharmaceuticals Company的产品开发高级总监，在那里他领导了Spritam®；和其他505B2管道产品的开发，Spritam®；是FDA批准的第一种使用三维打印制造的剂型。Jacob从2007年3月到2008年12月担任Panacos Pharmaceuticals Inc.（一家专注于人类免疫缺陷病毒（HIV）和其他主要人类病毒疾病的制药公司）配方开发主管，负责开发治疗HIV的一流成熟抑制剂。Jacob先生从2000年2月到2007年2月是Spherics，Inc.的创始科学家，研发总监和技术开发总监，该公司是一家制药公司，从事开发和制造中枢神经系统疾病，胃肠道疾病和癌症的口服药物产品。Jacob先生通过Spherics Inc.的505（b）（2）监管途径致力于开发用于治疗CNS疾病的生物粘附剂型。Jacob先生在布朗大学（Brown University）完成了生物与医学科学的本科学位和研究生教育，并在布朗大学（Brown University）分子药理学、生理学和生物技术系拥有活跃的客座教师任命。
Jules S. Jacob has served as Senior Director of CMC and Non-Clinical Development of the company and Rasna Therapeutics, Inc., respectively, since July 2017 and has over 25 years of drug development experience. Previously, Mr. Jacob was senior director of product development at Aprecia Pharmaceuticals Company, a drug delivery technology platform company, from March 2009 to July 2017 where he led the development of Spritam®, the first FDA-approved dosage form manufactured using 3-dimensional printing, and other 505b2 pipeline products. Mr. Jacob was director of formulation development at Panacos Pharmaceuticals Inc., a drug company focused on human immunodeficiency virus, or HIV, and other major human viral diseases, from March 2007 to December 2008 where he worked on the development of first-in-class maturation inhibitors for the treatment of HIV. Mr. Jacob was a founding scientist, director of R&D and director of technology development at Spherics, Inc., a pharmaceutical company that engaged in developing and manufacturing oral pharmaceutical products for CNS conditions, GI disorders, and cancer, from February 2000 to February 2007. Mr. Jacob worked on the development of bioadhesive dosage forms for treatment of CNS disorders, through the 505(b)(2) regulatory pathway at Spherics Inc. Mr. Jacob completed his undergraduate degree and graduate education in biological and medical sciences at Brown University and has an active visiting faculty appointment in the Department of Molecular Pharmacology, Physiology and Biotechnology at Brown University.- JulesS.Jacob自2017年7月起分别担任公司和Rasna Therapeutics，Inc.的CMC和非临床开发高级总监，拥有超过25年的药物开发经验。此前，Jacob先生于2009年3月至2017年7月担任药物输送技术平台公司Aprecia Pharmaceuticals Company的产品开发高级总监，在那里他领导了Spritam®；和其他505B2管道产品的开发，Spritam®；是FDA批准的第一种使用三维打印制造的剂型。Jacob从2007年3月到2008年12月担任Panacos Pharmaceuticals Inc.（一家专注于人类免疫缺陷病毒（HIV）和其他主要人类病毒疾病的制药公司）配方开发主管，负责开发治疗HIV的一流成熟抑制剂。Jacob先生从2000年2月到2007年2月是Spherics，Inc.的创始科学家，研发总监和技术开发总监，该公司是一家制药公司，从事开发和制造中枢神经系统疾病，胃肠道疾病和癌症的口服药物产品。Jacob先生通过Spherics Inc.的505（b）（2）监管途径致力于开发用于治疗CNS疾病的生物粘附剂型。Jacob先生在布朗大学（Brown University）完成了生物与医学科学的本科学位和研究生教育，并在布朗大学（Brown University）分子药理学、生理学和生物技术系拥有活跃的客座教师任命。
- Jules S. Jacob has served as Senior Director of CMC and Non-Clinical Development of the company and Rasna Therapeutics, Inc., respectively, since July 2017 and has over 25 years of drug development experience. Previously, Mr. Jacob was senior director of product development at Aprecia Pharmaceuticals Company, a drug delivery technology platform company, from March 2009 to July 2017 where he led the development of Spritam®, the first FDA-approved dosage form manufactured using 3-dimensional printing, and other 505b2 pipeline products. Mr. Jacob was director of formulation development at Panacos Pharmaceuticals Inc., a drug company focused on human immunodeficiency virus, or HIV, and other major human viral diseases, from March 2007 to December 2008 where he worked on the development of first-in-class maturation inhibitors for the treatment of HIV. Mr. Jacob was a founding scientist, director of R&D and director of technology development at Spherics, Inc., a pharmaceutical company that engaged in developing and manufacturing oral pharmaceutical products for CNS conditions, GI disorders, and cancer, from February 2000 to February 2007. Mr. Jacob worked on the development of bioadhesive dosage forms for treatment of CNS disorders, through the 505(b)(2) regulatory pathway at Spherics Inc. Mr. Jacob completed his undergraduate degree and graduate education in biological and medical sciences at Brown University and has an active visiting faculty appointment in the Department of Molecular Pharmacology, Physiology and Biotechnology at Brown University.
- Kunwar Shailubhai
Kunwar Shailubhai，2008年7月起担任公司首席科学官。2004年3月至2008年7月，他担任Synergy DE药物开发部高级副总裁。2003年5月至2004年3月，他担任Synergy DE研发部执行副总裁。2001至2003年4月，他担任Synergy DE药物开发部副总裁，主要负责临床前开发治疗结肠癌和胃肠道炎症药物的GC-C激动剂项目。1993至2000年，他在Monsanto Company担任癌症化学预防组的负责人。他之前在国立卫生研究院（National Institutes of Health）担任高级教员，且在University of Maryland担任助理教授。他1984年获得印度University of Baroda微生物学博士学位，2001年获得圣路易斯University of Missouri的工商管理硕士学位。
Kunwar Shailubhai has served as Chief Executive Officer, Chief Scientific Officer and Executive Director of the company since 2008. Since April, 2017 Dr. Shailubhai has served as Chief Executive Officer of Rasna Therapeutics, Inc. Dr. Shailubhai was a co-founder of Synergy Pharmaceuticals Inc. and served as Chief Scientific Officer from July 2008 to May 2017. From March 2004 until July 2008 Dr. Shailubhai served as Senior Vice President, Drug Discovery of Synergy, which at that time was a subsidiary of Callisto Pharmaceuticals, Inc. “Synergy DE”. From May 2003 until March 2004 Dr. Shailubhai served as executive vice president, R&D of Synergy DE. From 2001 to April 2003 Dr. Shailubhai held the position of Vice President, Drug Discovery at Synergy DE where he was chiefly responsible for the preclinical development of its GC-C agonist program for drugs to treat colon cancer and GI inflammation. Between 1993 and 2000 he was with Monsanto Company, serving as group leader of the cancer chemoprevention group. Dr. Shailubhai previously served as a senior staff fellow at the National Institutes of Health, and as an assistant professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology in 1984 from the University of Baroda, India, and his MBA in 2001 from the University of Missouri, St. Louis.- Kunwar Shailubhai，2008年7月起担任公司首席科学官。2004年3月至2008年7月，他担任Synergy DE药物开发部高级副总裁。2003年5月至2004年3月，他担任Synergy DE研发部执行副总裁。2001至2003年4月，他担任Synergy DE药物开发部副总裁，主要负责临床前开发治疗结肠癌和胃肠道炎症药物的GC-C激动剂项目。1993至2000年，他在Monsanto Company担任癌症化学预防组的负责人。他之前在国立卫生研究院（National Institutes of Health）担任高级教员，且在University of Maryland担任助理教授。他1984年获得印度University of Baroda微生物学博士学位，2001年获得圣路易斯University of Missouri的工商管理硕士学位。
- Kunwar Shailubhai has served as Chief Executive Officer, Chief Scientific Officer and Executive Director of the company since 2008. Since April, 2017 Dr. Shailubhai has served as Chief Executive Officer of Rasna Therapeutics, Inc. Dr. Shailubhai was a co-founder of Synergy Pharmaceuticals Inc. and served as Chief Scientific Officer from July 2008 to May 2017. From March 2004 until July 2008 Dr. Shailubhai served as Senior Vice President, Drug Discovery of Synergy, which at that time was a subsidiary of Callisto Pharmaceuticals, Inc. “Synergy DE”. From May 2003 until March 2004 Dr. Shailubhai served as executive vice president, R&D of Synergy DE. From 2001 to April 2003 Dr. Shailubhai held the position of Vice President, Drug Discovery at Synergy DE where he was chiefly responsible for the preclinical development of its GC-C agonist program for drugs to treat colon cancer and GI inflammation. Between 1993 and 2000 he was with Monsanto Company, serving as group leader of the cancer chemoprevention group. Dr. Shailubhai previously served as a senior staff fellow at the National Institutes of Health, and as an assistant professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology in 1984 from the University of Baroda, India, and his MBA in 2001 from the University of Missouri, St. Louis.